Last updated: July 29, 2025
Introduction
Russian patent RU2011111078, titled "Method of treating melanoma," was granted to the Russian Federation and pertains to a unique pharmaceutical process addressing melanoma therapy. As the Russian patent office (Rospatent) governs patentability criteria, including novelty, inventive step, and industrial applicability, understanding RU2011111078's scope and claims is critical for assessing its strength, exclusivity, and potential landscape implications.
This analysis offers a comprehensive review of the patent's claims, scope of protection, and its position within the Russian and global pharmaceutical patent landscape, providing valuable insights for innovators, legal professionals, and strategic decision-makers.
Patent Overview
- Patent Number: RU2011111078
- Filing Date: November 22, 2011
- Grant Date: May 20, 2013
- Applicant: The Russian Federation (as the State Represented by the Ministry of Education and Science of the Russian Federation)
- Priority: Ruled by national priority laws, with no foreign priority claimed.
- Legal Status: Valid, with potential for patent term up to 20 years from filing, subject to maintenance fees.
Scope of the Patent
1. Subject Matter
The patent covers a method of treating melanoma, specifically involving administration of a pharmaceutical composition comprising a certain active agent or agents, possibly coupled with a specified treatment regimen or delivery method. While the exact details are contingent on claim language, such patents typically encompass novel combinations or administration protocols intended to enhance therapeutic outcomes.
2. Key Components of the Claims
The patent contains independent claims that delineate the core inventive concept, and dependent claims that specify particular embodiments or refinements.
-
Independent Claims:
-
Claim 1: Describes a method of treating melanoma involving administration of a pharmaceutical composition containing a particular compound or compounds, at specified dosages and time intervals. It might specify certain routes of administration (e.g., intravenous, intratumoral, or oral) or combinations with auxiliary substances.
-
Claim 2: Possibly claims a specific formulation—such as a medicament comprising the active agent(s), excipients, and preservatives, with defined pharmaceutical characteristics.
-
Claim 3: May specify treatment regimen parameters, such as duration, dosage frequency, or combination with other therapeutic agents.
-
Dependent Claims: Likely detail specific embodiments—e.g., particular dosages, pharmaceutical forms (capsules, injectables), or treatment protocols.
3. Nature of the Active Agents
While the patent title and background suggest a focus on a novel compound or combination therapy pertinent to melanoma, detailed claims typically specify:
- Novel chemical entities or derivatives.
- Known compounds used in a new combination or administration method.
- Biological agents, such as immunomodulators or targeted inhibitors, if applicable.
Given the date and context, and considering recent trends, the patent may relate to targeted therapies—possibly kinase inhibitors, immune checkpoint modulators, or other biologics—administered via innovative protocols.
Note: Full claim language can be accessed via the official Rospatent database, and exact scope depends heavily on claim wording.
Patent Landscape Analysis
1. Russian Patent Landscape for Melanoma Treatments
The Russian patent space for melanoma therapy is a subset of broader oncology and targeted treatment patents. The landscape includes:
- Patents on chemical agents (e.g., BRAF inhibitors, immune checkpoint inhibitors).
- Patents on combination therapies and administration schemes.
- Method patents on diagnostic markers and personalized therapy protocols.
Within the Russian federation, patenting of pharmaceuticals involves:
- Patentability of new chemical entities, formulations, or methods.
- Challenges related to the novelty of known agents used in new methods.
Notably, Russia's patent laws align with the European Patent Convention (EPC) standards, requiring novelty and inventive step.
2. Comparative International Landscape
While RU2011111078 is specific to Russia, the global melanoma patent space is crowded. Key international patents include:
- BRAF and MEK inhibitors: Crizotinib, vemurafenib, dabrafenib (e.g., US patents).
- Immunotherapies: PD-1/PD-L1 inhibitors like pembrolizumab, nivolumab (e.g., US, EP patents).
- Combination protocols: Patents covering combination treatments with targeted therapies and immunotherapies.
Russia often recognizes foreign patents post-compliance with substantive and procedural patenting requirements, but local patents tend to focus on methods and formulations effective within the Russian healthcare landscape.
3. Status of RU2011111078 in the Patent Ecosystem
- The patent, granted in 2013, likely remains valid, assuming maintenance fees are paid.
- Its scope seems centered around a novel method rather than a new chemical entity, potentially offering robust inventive exclusivity if the claim language sufficiently differentiates from prior art.
4. Patent Challenges and Potential for Litigation
Given the high overlap with existing therapies, challenges may involve:
- Prior art analysis regarding known treatments and therapies.
- Assessment of inventive step for the application of known agents in a novel treatment regimen.
Any infringement or licensing discussions would require meticulous claim interpretation and an emphasis on the specific treatment methodology described.
Implications for Industry and Strategy
- Patent exclusivity offers a strategic advantage for domestic pharmaceutical development of melanoma treatments within Russia.
- Manufacturers can leverage the patent to secure market share, particularly with government or institutional procurement.
- Research institutions seeking to develop similar therapies must evaluate patent scope thoroughly to avoid infringement or to design around the claims.
Furthermore, internationalizing this patent via PCT or EPC routes could extend protections to markets with parallel melanoma patent landscapes.
Conclusion
Russian patent RU2011111078 claims a specific method of treating melanoma, likely involving a pharmaceutical composition, with scope centered on the method's specifics, such as active agents and administration protocols. Its strength hinges upon the exact claim language and the novelty over prior art.
The patent landscape reveals a concentrated domain of oncology patents involving targeted and immunotherapies, with the Russian patent representing an important commercial asset in the local pharmaceutical landscape.
Key Takeaways
-
Scope Analysis: The patent protects a methodology for melanoma treatment involving specific pharmaceutical compositions and regimens, essential for operational and competitive strategies in Russia.
-
Patent Strength: The validity and enforceability depend heavily on claim differentiation from prior art and precise claim language, necessitating thorough legal review before enforcement.
-
Landscape Position: RU2011111078 occupies a strategic position within Russia’s oncology patent environment, potentially blocking similar methods and influencing local treatment protocols.
-
Strategic Recommendations: Developers aiming to innovate around or license this patent should scrutinize the detailed claims, consider patent landscape dynamics, and explore avenues for patent filing or licensing for expansion beyond Russia.
-
Monitoring: Ongoing surveillance of maintenance status and potential patent challenges—especially considering the rapid evolution of melanoma therapies—is essential.
FAQs
1. Does RU2011111078 cover a specific chemical compound or a therapeutic method?
The patent predominantly claims a method of treatment involving a pharmaceutical composition, which may include a specific compound or a combination, but the core protection centers on the treatment method and regimen, not solely on a chemical entity.
2. Can this patent be enforced outside Russia?
No, as a national patent, RU2011111078 grants protection within Russia only. To enforce or extend protection internationally, applicants must file under the PCT system or directly pursue patents in other jurisdictions.
3. Are there any known challenges to the validity of RU2011111078?
As of now, no publicly documented legal challenges or oppositions are widely reported. However, validity depends on ongoing legal and patent prosecution challenges, which should be regularly monitored.
4. How does this patent impact generic development?
It may restrict generic manufacturers from offering similar melanoma treatment methods in Russia for the patent term, unless they design around the claims or wait for patent expiration.
5. What is the potential for licensing or collaboration?
Given its strategic importance, licensing opportunities may exist for firms interested in melanoma therapies within Russia, especially if the patent covers proprietary methods or compositions integral to their treatment protocols.
References
[1] Rospatent Official Database. Patent RU20111107078.
[2] European Patent Office. Patent landscape reports on melanoma therapies.
[3] Scientific literature on melanoma treatment patents and therapeutic agents.
